

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of the claims in the application:

**Listing of Claims:**

Claims 1-99 (canceled).

Claim 100 (new): A haptен-carrier conjugate comprising at least one haptен derived from nicotine and at least one carrier containing a T cell epitope and wherein said haptен and said carrier are linked by a branch selected from the group of chemical moieties identified by CJ reference number consisting of:

CJ 0	Q
CJ 1	(CH <sub>2</sub> ) <sub>n</sub> Q
CJ 1.1	CO <sub>2</sub> Q
CJ 1.2	COQ
CJ 1.3	OCH <sub>3</sub>
CJ 2	OCO(CH <sub>2</sub> ) <sub>n</sub> Q
CJ 2.1	OCOCH=Q
CJ 2.2	OCOCH(O)CH <sub>2</sub>
CJ 2.3	OCO(CH <sub>2</sub> ) <sub>n</sub> CH(O)CH <sub>2</sub>
CJ 3	CO(CH <sub>2</sub> ) <sub>n</sub> COQ
CJ 3.1	CO(CH <sub>2</sub> ) <sub>n</sub> CNQ
CJ 4	OCO(CH <sub>2</sub> ) <sub>n</sub> COQ
CJ 4.1	OCO(CH <sub>2</sub> ) <sub>n</sub> CNQ
CJ 5	CH <sub>2</sub> OCO(CH <sub>2</sub> ) <sub>n</sub> COQ
CJ 5.1	CH <sub>2</sub> OCO(CH <sub>2</sub> ) <sub>n</sub> CNQ
CJ 6	CONH(CH <sub>2</sub> ) <sub>n</sub> Q
CJ 7	Y(CH <sub>2</sub> ) <sub>n</sub> Q
CJ 7.1	CH <sub>2</sub> Y(CH <sub>2</sub> ) <sub>n</sub> Q
CJ 8	OCOCH(OH)CH <sub>2</sub> Q
CJ 8.1	OCO(CH <sub>2</sub> ) <sub>n</sub> CH(OH)CH <sub>2</sub> Q
CJ 9	OCOC <sub>6</sub> H <sub>5</sub>
CJ 10	as identified in the application as FIG. 1b
CJ 11	YCO(CH <sub>2</sub> ) <sub>n</sub> COQ;

and wherein n is an integer, and Q is the carrier.

Claim 101 (new): A haptен-carrier conjugate according to claim 100, wherein n is from about 2 to about 20.

Claim 102 (new): A haptен-carrier conjugate according to claim 100, wherein Y is selected from the group consisting of S, O and NH.

Claim 103 (new): A haptен-carrier conjugate according to claim 100, wherein the carrier is selected from:- proteins or peptides, bacterial toxins or products, subvirals, lectins, allergens and fragments of allergens, malarial protein antigen, artificial multi-antigenic peptides, and modifications, analogs and derivatives thereof.

Claim 104 (new): The haptен-carrier conjugate of claim 100, wherein greater than one haptен is coupled to the carrier.

Claim 105 (new): A method of treating nicotine addiction in a mammal comprising administering a therapeutically effective amount of the haptен-carrier conjugate of claim 100 to a subject mammal.

Claim 106 (new): A method according to claim 105, wherein said haptен-carrier conjugate is administered mucosally and comprises co-polymer microspheres optionally of poly(lactide-co-glycolide) co-polymer.

Claim 107 (new): A method according to claim 105, wherein said haptен-carrier conjugate is administered as a topical preparation and which preparation optionally has a dynamic viscosity greater than water.

Claim 108 (new): A method according to claim 105, wherein said haptен-carrier conjugate is administered as an injectible, sterile solution.

Claim 109 (new): A pharmaceutical preparation, which comprises (a) the haptен-carrier conjugate of claim 105, and also (b) adjuvant.

Claim 110 (new): A process for preparing a conjugate according to claim 100, which comprises linking the hapten and the carrier containing a T cell epitope by cross linking with a compound selected from: a carboxylic acid derived active ester, a mixed anhydride, an acyl azide, an acyl halide, an imino ester.